On Monday, 21 October 2019, JGL organised special celebrations at several locations in Zagreb and Rijeka. This was done to mark the launch of Magnolicomb HCT 5 mg/160 mg/12.5 mg, 5 mg/160 mg/25 mg and 10 mg/160 mg/12.5 mg film-coated tablets as the first and only generic parallel, on the first day after the expiration of the patent!
CEO Mislav Vučić addressed the employees at the main event in the Pharma Valley complex, congratulating everyone involved in JGL’s teams on their great accomplishment. The main celebration venue was specially decorated for the occasion with Magnolicomb visuals on desserts and balloons. The stars of the show were the elegant magnolia flowers that the drug was named after, which made quite an impression on all of the attendees.
It is worth mentioning that Magnolicomb HCT has been approved as part of the European decentralised procedure (DCP), making it the first prescription drug from JGL to be authorised in such a way in Croatia, which is more than enough reason to celebrate!